Confidentiality Definition Comes Closer After AbbVie Drops EMA Cases
This article was originally published in The Pink Sheet Daily
Executive Summary
AbbVie’s decision to drop two cases against the EMA is likely to boost clinical trial transparency as well as bring drug regulators and the industry closer to a joint definition of commercial confidentiality.
You may also be interested in...
Clinical Trials Transparency: EMA Delay Gives Industry Initiative More Time To Take Root
EMA’s plans for access to clinical trials data not set to be ready until well into 2014.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.